[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA CancerJ Clin,20217,1(3):209-249.
[2] Srivastava A, Sharma H, Khanna S, et al. Interleukin-6 induced proliferation is attenuated by transforming growth factor-β-induced signaling in human hepatocellular carcinoma cells[J].Front Oncol, 20221,1:811941.
[3] Yang J, Wang J, Luo J. Decreased IL-6 induces sensitivity of hepatocellular carcinomacells to sorafenib[J]. Pathol Res Pract,2019,215(10):152565.
[4] Xu J, Lin H, Wu G, et al. IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma[J]. Front Oncol,2021,11:760971.
[5] Bergmann J, Müller M, Baumann N, et al. IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice[J]. Hepatology,2017,65(1):89-103.
[6] Wang Y, Miao X, Jiang Y, et al. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma[J]. Cell Death Dis,2022,13(2):146.
[7] Chen J, Chen J, Huang J, et al. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway[J]. Aging (Albany NY),2019,11(23):10839-10860.
[8] Wen W, Han T, Chen C, et al. Cyclin G1 expands liver tumor-initiating cells by Sox induction via Akt/mTOR signaling[J]. Mol Cancer Ther,2013,12(9):1796-1804.
[9] Duncan L, Shay C, Teng Y. PI3K Isoform-Selective Inhibitors in Cancer[J]. Adv Exp Med Biol,2020,1255:165-173.
[10] Ma W, Sze KM, Chan LK, et al. RhoE/ROCK2 regulates chemoresistance through NF-κB/IL-6/ STAT3 signaling in hepatocellular carcinoma[J]. Oncotarget,2016,7(27):41445-41459.
[11] 国家卫生健康委员会办公厅. 原发性肝癌诊疗指南(2022年版)[J].中国实用外科杂志,2022,42(3):241-273.
[12] Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma[J]. Liver Int,2019,39(12):2214-2229.
[13] Lersritwimanmaen P, Nimanong S. Hepatocellular carcinoma surveillance: benefit of serum alfa-fetoprotein in real-world practice[J]. Euroasian J Hepatogastroenterol,2018,8(1):83-87.
[14] Porta C, De Amici M, Quaglini S, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma[J]. Ann Oncol,2008,19(2):353-358.
[15] Yang J R, Wang J, Li H M, et al. IL-6 promoter hypomethylation acts as a diagnostic biomarker in hepatitis B virus-associated hepatocellular carcinoma[J]. Front Oncol,2022,12:746643.
[16] Li H, Lan T, Liu H, et al. IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma[J]. Hepatology,2022,75(6):1402-1419.
[17] Pang X H, Zhang J P, Zhang Y J, et al. Preoperative levels of serum interleukin-6 in patients with hepatocellular carcinoma[J]. Hepatogastroenterology,2011,58(110-111):1687-1693.
[18] Yang X, Liang L, Zhang X F, et al. MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway[J]. Hepatology,2013,58(1):158-170.
[19] Sheng T, Wang B, Wang S Y, et al. The relationship between serum interleukin-6 and the Recurrence of Hepatitis B virus related hepatocellular carcinoma after curative resection[J]. Medicine (Baltimore),2015,94(24):e941.
[20] Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol,2019,37(24):2141-2151.
[21] Zhang M, Zhang S, Yang Z, et al. Association between the expression levels of IL-6 and IL-6R in the hepatocellular carcinoma microenvironment and postoperative recurrence[J]. Oncol Lett,2018,16(6):7158-7165.
[22] Lee H L, Jang J W, Lee S W, et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization[J]. Sci Rep,2019,9(1):3260.
[23] Loosen S H, Schulze-Hagen M, Leyh C, et al. IL-6 and IL-8 serum levels predict tumor response and overall survival after TACE for primary and secondary hepatic malignancies[J]. Int J Mol Sci,2018,19(6):1766.
[24] Huang Z, Lu W, Yu N, et al. Systemic inflammatory response predicts poor prognoses in Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma with transarterial chemoembolization: a prospective study[J]. Transl Cancer Res,2019,8(7):2552-2563.
[25] Wu Y, Fan W, Xue M, et al. Postintervention interleukin-6 (IL-6) level, rather than the pretreatment or dynamic changes of IL-6, as an early practical marker of tumor response in hepatocellular carcinoma treated with transarterial chemoembolization[J]. Oncologist,2019,24(12):e1489-e1495.
[26] Wang H, Zhang G, Fan W, et al. Clinical significance of peripheral blood lymphocyte subtypes and cytokines in patients with hepatocellular carcinoma treated with TACE[J]. Cancer Manag Res,2022,14:451-464.
[27] Ji Q, Fu Y, Zhu X, et al. Effect of RFA and TACE combined with postoperative cytokine-induced killer cell immunotherapy in primary hepatocellular carcinoma[J]. BUON,2021,26(1):235-242.
[28] Lai S C, Su Y T, Chi C C, et al. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation[J]. J Exp Clin Cancer Res,2019,38(1):474.
[29] Shao Y Y, Lin H, Li Y S, et al. High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma[J]. Jpn J Clin Oncol,2017,47(10):949-953.
[30] Öcal O, Schütte K, Kupčinskas J, et al. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial[J]. Cancer Res Clin Oncol,2022,148(2):475-485.
[31] Shao Y, Hsu C, Huang C, et al. Use of plasma angiogenesis-related factors to investigate the association of interleukin 8 and interleukin 6 levels with efficacy of sorafenib-based antiangiogenic therapy in patients with advanced hepatocellular carcinoma (HCC)[J]. Clin Oncol,2011,29(4):199.
[32] Chen M F, Kuan F C, Yen T C, et al. IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus[J]. Oncotarget,2014,5(18):8716-8728.
[33] Myojin Y, Kodama T, Sakamori R, et al. Interleukin-6 is a circulating prognostic biomarker for hepatocellular carcinoma patients treated with combined immunotherapy[J]. Cancers (Basel),2022,14(4):883.
[34] Lin Y X, Wu X B, Zheng C W, et al. Mechanistic investigation on the regulation of FABP1 by the IL-6/miR-603 signaling in the pathogenesis of hepatocellular carcinoma[J]. Biomed Res Int,2021,2021:8579658.
[35] Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy[J]. Hepatol,2016,64(6):1403-1415.
[36] Dai Z, Wang X, Peng R, et al. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma[J]. Cancer Lett,2022,524:161-171.
[37] Ruan B, Liu W, Chen P, et al. NVP-BEZ235 inhibits thyroid cancer growth by p53- dependent/independent p21 upregulation[J]. Int J Biol Sci,2020,16(4):682-693.
[38] Yu C C, Huang S Y, Chang S F, et al. The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma[J]. Molecules,2020,25(10):2454.
[39] Wang Y, Miao X, Jiang Y, et al. The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma[J]. Cell Death Dis,2022,13(2):146.
[40] Wan S, Zhao E, Kryczek I, et al. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells[J]. Gastroenterology,2014,147(6):1393-1404. |
